Jiangsu Hengrui Medicine. has filed a patent for a method using an NK1 antagonist prodrug compound and a 5-HT3 receptor antagonist to prevent or treat nausea and vomiting. The method involves administering the compound of formula (I) or its salt along with the 5-HT3 receptor antagonist to patients in need. GlobalData’s report on Jiangsu Hengrui Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Jiangsu Hengrui Medicine Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jiangsu Hengrui Medicine, Cancer treatment biomarkers was a key innovation area identified from patents. Jiangsu Hengrui Medicine's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240016822A1) describes a method for preventing or treating nausea and/or vomiting in patients by administering a compound of formula (I) or a pharmaceutically acceptable salt along with a 5-HT3 receptor antagonist. The 5-HT3 receptor antagonist can be selected from a specific group including granisetron, ondansetron, ramosetron, tropisetron, palonosetron, and dolasetron. The compound of formula (I) or its salt is administered at a dose ranging from 10-500 mg, while the 5-HT3 receptor antagonist is administered at a dose of 0.075-1 mg. The frequency of administration for both components can vary from once a day to once every two weeks, depending on the patient's needs.

Furthermore, the method outlined in the patent application is specifically targeted towards preventing or treating nausea and/or vomiting induced by various factors such as chemotherapy, radiotherapy, or postoperative procedures. The pharmaceutical composition mentioned in the claims includes the compound of formula (I) or its salt. Additionally, a pharmaceutical package containing the composition along with a 5-HT3 receptor antagonist is also part of the patent application. Notably, the method suggests administering the compound and the antagonist either after a vomiting-inducing event or shortly before such an event occurs, ensuring timely and effective treatment. One of the specific 5-HT3 receptor antagonists mentioned in the claims is palonosetron, which can be used in conjunction with the compound of formula (I) for the prevention or treatment of nausea and vomiting in patients.

To know more about GlobalData’s detailed insights on Jiangsu Hengrui Medicine, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies